| Title	PDLIM2 is a marker of adhesion and ß-catenin activity in triple-negative breast cancer
Authors	Cox, Orla T.;Edmunds, Shelley J.;Simon-Keller, Katja;Li, Bo;Moran, Bruce;Buckley, Niamh E.;Bustamante- Garrido, Milán F.;Healy, Nollaig;O'Flanagan, Ciara H.;Gallagher, William M.;Kennedy, Richard D.;Bernards, René;Caldas, Carlos;Chin, Suet-Feung;Marx, Alexander;O'Connor, Rosemary
Publication date	2019-03-18
Original Citation	Cox, O. T., Edmunds, S. J., Simon-Keller, K., Li, B., Moran, B., Buckley, N. E., Bustamante-Garrido, M., Healy, N., O'Flanagan, C. H., Gallagher, W. M., Kennedy, R. D., Bernards, R., Caldas, C., Chin, S.-F., Marx, A. and O'Connor, R. (2019) 'PDLIM2 is a marker of adhesion and ß-catenin activity in triple-negative breast cancer', Cancer Research, 79(10), pp. 2619-2633. doi: 10.1158/0008-5472.CAN-18-2787
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://cancerres.aacrjournals.org/content/79/10/2619 - 10.1158/0008-5472.CAN-18-2787
Rights	© 2019, American Association for Cancer Research. All rights reserved.
Download date	2025-08-03 23:36:00
Item downloaded from	https://hdl.handle.net/10468/8050

A

B

PDLIM2 IHC:
Normal tissue within tumor samples

RATHER Cohorts

C

PDLIM2 Negative/Positive versus	Spearman Correlation	p value
	ρ	P
Patient Age	-0.086	0.392
Tumor Size	-0.11	0.276
Number of Lymph Nodes	-0.066	0.519
Histological Grade	-0.166	0.097
Adjuvant Chemotherapy	-0.093	0.353

Supplementary Figure 2, related to Figure 2:

A: PDLIM2 expression shown by weighted score of IHC staining presented as percentage of tumors within each TNBC subtype in RATHER (NKI, CAM) and Heidelberg cohorts. **B:** Representative micrographs of IHC staining for PDLIM2 in regions of non-tumor tissue (N) within tumors (T) from the Heidelberg cohort, highlighting lack of immuno-reactivity of normal cells (N) compared with PDLIM2-positive Stroma (S). Images are from a PDLIM2-negative tumor (i) and a PDLIM2-positive tumor (ii). Scalebars are 100μm (100x) and 50μm

(200x). **C:** Statistical evaluation of PDLIM2 expression (negative/positive) correlation with clinico-pathological parameters from patient data available for the RATHER cohorts; Kaplan Meier survival curves showing the relationship between PDLIM2 expression and breast cancer-specific survival, recurrence-free survival and distant recurrence-free survival in the RATHER cohorts (n=102). The correlations between negative/positive expression of PDLIM2 and clinicopathologic variables were evaluated using the Spearman's rank correlation coefficient method. A two-tailed test with p value < 0.05 is considered to be significant.